Enavogliflozin Shows Superior Glucose-Lowering Power in Patients with Renal Impairment: Study

Results:

• In the mildly reduced eGFR group, enavogliflozin demonstrated a significantly greater reduction in adjusted mean change of HbA1c and fasting plasma glucose levels at week 24 compared to dapagliflozin (-0.94% vs. -0.77%, P = 0.0196).
• Notably, the glucose-lowering effect of enavogliflozin was more pronounced when combined with dipeptidyl peptidase-4 inhibitors.
• Enavogliflozin exhibited potent blood glucose-lowering effects regardless of renal function.
• Conversely, dapagliflozin displayed diminishing efficacy with decreasing renal function.
• Enavogliflozin showcased a higher urinary glucose excretion rate in both patient groups.
• Additionally, the homeostatic model assessment revealed a marked decrease in insulin resistance with enavogliflozin.
• Blood pressure, weight loss, and homeostasis model assessment of beta-cell function values did not significantly differ between enavogliflozin and dapagliflozin.
• Adverse events were comparable between the two drugs.

The study concludes that enavogliflozin's glucose-lowering efficacy surpasses that of dapagliflozin, particularly in patients with type 2 diabetes and mild renal function impairment. This superiority is attributed to enavogliflozin's potent urinary glucose excretion-promoting ability. The emergence of such robust SGLT-2 inhibitors holds promise as an attractive option for patients with inadequate glycemic control and decreased renal function.

Further reading: Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials. Doi: https://doi.org/10.1186/s12933-024-02155-9